|
US4897355A
(en)
|
1985-01-07 |
1990-01-30 |
Syntex (U.S.A.) Inc. |
N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US4946787A
(en)
|
1985-01-07 |
1990-08-07 |
Syntex (U.S.A.) Inc. |
N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US5049386A
(en)
|
1985-01-07 |
1991-09-17 |
Syntex (U.S.A.) Inc. |
N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US5549910A
(en)
|
1989-03-31 |
1996-08-27 |
The Regents Of The University Of California |
Preparation of liposome and lipid complex compositions
|
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
|
JP3218637B2
(ja)
|
1990-07-26 |
2001-10-15 |
大正製薬株式会社 |
安定なリポソーム水懸濁液
|
|
JP2958076B2
(ja)
|
1990-08-27 |
1999-10-06 |
株式会社ビタミン研究所 |
遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
|
|
US6174666B1
(en)
|
1992-03-27 |
2001-01-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of eliminating inhibitory/instability regions from mRNA
|
|
US5741516A
(en)
|
1994-06-20 |
1998-04-21 |
Inex Pharmaceuticals Corporation |
Sphingosomes for enhanced drug delivery
|
|
US5885613A
(en)
|
1994-09-30 |
1999-03-23 |
The University Of British Columbia |
Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
|
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
|
US5811524A
(en)
|
1995-06-07 |
1998-09-22 |
Idec Pharmaceuticals Corporation |
Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
|
|
US5738868A
(en)
|
1995-07-18 |
1998-04-14 |
Lipogenics Ltd. |
Liposome compositions and kits therefor
|
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
|
MX336813B
(es)
|
1996-02-09 |
2016-02-02 |
Abbvie Biotechnology Ltd |
Anticuerpos humanos que ligan el tnfa humano.
|
|
US5928906A
(en)
|
1996-05-09 |
1999-07-27 |
Sequenom, Inc. |
Process for direct sequencing during template amplification
|
|
AU733310C
(en)
|
1997-05-14 |
2001-11-29 |
University Of British Columbia, The |
High efficiency encapsulation of charged therapeutic agents in lipid vesicles
|
|
US5891994A
(en)
|
1997-07-11 |
1999-04-06 |
Thymon L.L.C. |
Methods and compositions for impairing multiplication of HIV-1
|
|
GB9720585D0
(en)
|
1997-09-26 |
1997-11-26 |
Smithkline Beecham Biolog |
Vaccine
|
|
US6320017B1
(en)
|
1997-12-23 |
2001-11-20 |
Inex Pharmaceuticals Corp. |
Polyamide oligomers
|
|
EP1155056A4
(en)
|
1998-12-04 |
2004-05-12 |
Mosaic Technologies Inc |
METHOD OF IMMOBILIZING OLIGONUCLEOTIDES
|
|
BR0107972A
(pt)
|
2000-01-31 |
2002-11-05 |
Smithkline Beecham Biologicals |
Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
|
|
WO2002087541A1
(en)
|
2001-04-30 |
2002-11-07 |
Protiva Biotherapeutics Inc. |
Lipid-based formulations for gene transfer
|
|
FR2824431A1
(fr)
|
2001-05-03 |
2002-11-08 |
Mitsubishi Electric Inf Tech |
Methode et dispositif de reception de signal
|
|
WO2004090108A2
(en)
|
2003-04-03 |
2004-10-21 |
Alnylam Pharmaceuticals |
Irna conjugates
|
|
CA2521464C
(en)
|
2003-04-09 |
2013-02-05 |
Alnylam Pharmaceuticals, Inc. |
Irna conjugates
|
|
EP1664316B1
(en)
|
2003-09-15 |
2012-08-29 |
Protiva Biotherapeutics Inc. |
Polyethyleneglycol-modified lipid compounds and uses thereof
|
|
US20060246079A1
(en)
|
2003-11-14 |
2006-11-02 |
Morrow Phillip R |
Neutralizing human antibodies to anthrax toxin
|
|
WO2006069782A2
(en)
|
2004-12-27 |
2006-07-06 |
Silence Therapeutics Ag. |
Lipid complexes coated with peg and their use
|
|
CA2569664C
(en)
|
2004-06-07 |
2013-07-16 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
|
JP4764426B2
(ja)
|
2004-06-07 |
2011-09-07 |
プロチバ バイオセラピューティクス インコーポレイティッド |
カチオン性脂質および使用方法
|
|
US20060051405A1
(en)
|
2004-07-19 |
2006-03-09 |
Protiva Biotherapeutics, Inc. |
Compositions for the delivery of therapeutic agents and uses thereof
|
|
AU2005330637B2
(en)
|
2004-08-04 |
2012-09-20 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
|
|
US7404969B2
(en)
|
2005-02-14 |
2008-07-29 |
Sirna Therapeutics, Inc. |
Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
|
|
CN101500548A
(zh)
|
2006-08-18 |
2009-08-05 |
弗·哈夫曼-拉罗切有限公司 |
用于体内递送多核苷酸的多缀合物
|
|
CA2927045A1
(en)
|
2006-10-03 |
2008-04-10 |
Muthiah Manoharan |
Lipid containing formulations
|
|
US7879326B2
(en)
|
2007-06-15 |
2011-02-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Human neutralizing monoclonal antibodies to H5N1 influenza A virus
|
|
WO2009018332A1
(en)
|
2007-08-01 |
2009-02-05 |
Alnylam Pharmaceuticals, Inc. |
Single-stranded and double-stranded oligonucleotides comprising a metal-chelating ligand
|
|
WO2009082606A2
(en)
|
2007-12-04 |
2009-07-02 |
Alnylam Pharmaceuticals, Inc. |
Folate conjugates
|
|
WO2009073809A2
(en)
|
2007-12-04 |
2009-06-11 |
Alnylam Pharmaceuticals, Inc. |
Carbohydrate conjugates as delivery agents for oligonucleotides
|
|
WO2009086558A1
(en)
|
2008-01-02 |
2009-07-09 |
Tekmira Pharmaceuticals Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
|
ITTO20080204A1
(it)
|
2008-03-17 |
2009-09-18 |
Pomona Biotechnologies Llc |
Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
|
|
CA2721333C
(en)
|
2008-04-15 |
2020-12-01 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for nucleic acid delivery
|
|
WO2009132131A1
(en)
|
2008-04-22 |
2009-10-29 |
Alnylam Pharmaceuticals, Inc. |
Amino lipid based improved lipid formulation
|
|
ITTO20080398A1
(it)
|
2008-05-27 |
2009-11-28 |
Pomona Biotechnologies Llc |
Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
|
|
EP2313435A4
(en)
|
2008-07-01 |
2012-08-08 |
Aveo Pharmaceuticals Inc |
FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
|
|
US8883211B2
(en)
|
2008-07-10 |
2014-11-11 |
Serina Therapeutics, Inc. |
Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds
|
|
CA2731686C
(en)
|
2008-07-25 |
2020-04-07 |
Institute For Research In Biomedicine |
Neutralizing anti-influenza a virus antibodies and uses thereof
|
|
GB0813784D0
(en)
|
2008-07-28 |
2008-09-03 |
Ct Integrated Photonics Ltd |
Optical intergration system
|
|
CA2740000C
(en)
|
2008-10-09 |
2017-12-12 |
Tekmira Pharmaceuticals Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
WO2010048536A2
(en)
|
2008-10-23 |
2010-04-29 |
Alnylam Pharmaceuticals, Inc. |
Processes for preparing lipids
|
|
CN111808084A
(zh)
|
2008-11-10 |
2020-10-23 |
阿布特斯生物制药公司 |
用于递送治疗剂的新型脂质和组合物
|
|
US8722082B2
(en)
|
2008-11-10 |
2014-05-13 |
Tekmira Pharmaceuticals Corporation |
Lipids and compositions for the delivery of therapeutics
|
|
EP3243504A1
(en)
|
2009-01-29 |
2017-11-15 |
Arbutus Biopharma Corporation |
Improved lipid formulation
|
|
MA33208B1
(fr)
|
2009-03-25 |
2012-04-02 |
Genentech Inc |
Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
|
|
WO2010119991A2
(en)
|
2009-04-17 |
2010-10-21 |
Takeda Pharmaceutical Company Limited |
Novel method of treating cancer
|
|
SG10201911942UA
(en)
|
2009-05-05 |
2020-02-27 |
Muthiah Manoharan |
Lipid compositions
|
|
CA2761648C
(en)
|
2009-05-11 |
2019-03-12 |
Crucell Holland B.V. |
Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
|
|
IT1395961B1
(it)
|
2009-06-01 |
2012-11-02 |
Pomona Biotechnologies Llc |
Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
|
|
KR101766408B1
(ko)
|
2009-06-10 |
2017-08-10 |
알닐람 파마슈티칼스 인코포레이티드 |
향상된 지질 조성물
|
|
US8569256B2
(en)
|
2009-07-01 |
2013-10-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
|
WO2011000107A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for delivery of therapeutic agents to solid tumors
|
|
ES2579936T3
(es)
|
2009-08-20 |
2016-08-17 |
Sirna Therapeutics, Inc. |
Nuevos lípidos catiónicos con diversos grupos de cabeza para el suministro oligonucleotídico
|
|
US9222086B2
(en)
|
2009-09-23 |
2015-12-29 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
|
WO2011066651A1
(en)
|
2009-12-01 |
2011-06-09 |
Protiva Biotherapeutics, Inc. |
Snalp formulations containing antioxidants
|
|
EP3296398A1
(en)
|
2009-12-07 |
2018-03-21 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
|
EP2525781A1
(en)
|
2010-01-22 |
2012-11-28 |
Schering Corporation |
Novel cationic lipids for oligonucleotide delivery
|
|
RU2012153241A
(ru)
|
2010-05-11 |
2014-06-20 |
Авео Фармасьютикалз, Инк. |
Антитела к fgfr2
|
|
WO2011141704A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc |
Novel cyclic cationic lipids and methods of use
|
|
US20130123338A1
(en)
|
2010-05-12 |
2013-05-16 |
Protiva Biotherapeutics, Inc. |
Novel cationic lipids and methods of use thereof
|
|
DK2575767T3
(en)
|
2010-06-04 |
2017-03-13 |
Sirna Therapeutics Inc |
HOWEVER UNKNOWN LOW MOLECULAR CATIONIC LIPIDS TO PROCESS OIGONUCLEOTIDES
|
|
EP3323830B1
(en)
|
2010-06-19 |
2023-08-23 |
Memorial Sloan-Kettering Cancer Center |
Anti-gd2 antibodies
|
|
US9006417B2
(en)
|
2010-06-30 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
|
WO2012016184A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
|
CA2806021C
(en)
|
2010-08-13 |
2019-05-21 |
Roche Glycart Ag |
Anti-fap antibodies and methods of use
|
|
LT4226941T
(lt)
|
2010-08-31 |
2025-01-10 |
Glaxosmithkline Biologicals Sa |
Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
|
|
CA2812046A1
(en)
|
2010-09-15 |
2012-03-22 |
Alnylam Pharmaceuticals, Inc. |
Modified irna agents
|
|
CA2809858C
(en)
|
2010-09-20 |
2019-11-12 |
Sirna Therapeutics, Inc. |
Novel low molecular weight cationic lipids for oligonucleotide delivery
|
|
CA2811430A1
(en)
|
2010-09-30 |
2012-04-05 |
Merck Sharp & Dohme Corp. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
|
EP3485913A1
(en)
|
2010-10-21 |
2019-05-22 |
Sirna Therapeutics, Inc. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
|
WO2012068187A1
(en)
|
2010-11-19 |
2012-05-24 |
Merck Sharp & Dohme Corp. |
Poly(amide) polymers for the delivery of oligonucleotides
|
|
CA2824526C
(en)
|
2011-01-11 |
2020-07-07 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
|
SG185832A1
(en)
|
2011-05-10 |
2012-12-28 |
Agency Science Tech & Res |
Fgfr1 antibodies and treatment of cancer
|
|
CA2828890A1
(en)
|
2011-04-07 |
2012-10-11 |
Genentech, Inc. |
Anti-fgfr4 antibodies and methods of use
|
|
WO2012162210A1
(en)
|
2011-05-26 |
2012-11-29 |
Merck Sharp & Dohme Corp. |
Ring constrained cationic lipids for oligonucleotide delivery
|
|
EP4115875A1
(en)
|
2011-07-06 |
2023-01-11 |
GlaxoSmithKline Biologicals S.A. |
Liposomes having useful n:p ratio for delivery of rna molecules
|
|
WO2013016058A1
(en)
|
2011-07-22 |
2013-01-31 |
Merck Sharp & Dohme Corp. |
Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
|
|
MX366055B
(es)
|
2011-08-31 |
2019-06-26 |
Novartis Ag |
Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno.
|
|
EP3456317B1
(en)
|
2011-09-27 |
2025-09-24 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted pegylated lipids
|
|
AR088941A1
(es)
|
2011-11-23 |
2014-07-16 |
Bayer Ip Gmbh |
Anticuerpos anti-fgfr2 y sus usos
|
|
WO2013086354A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
WO2013086373A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
|
AU2012347605B2
(en)
|
2011-12-07 |
2017-09-21 |
Alnylam Pharmaceuticals, Inc. |
Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
|
|
JP6182457B2
(ja)
|
2011-12-12 |
2017-08-16 |
協和発酵キリン株式会社 |
カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子
|
|
WO2013116126A1
(en)
|
2012-02-01 |
2013-08-08 |
Merck Sharp & Dohme Corp. |
Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
|
|
EP2817287B1
(en)
|
2012-02-24 |
2018-10-03 |
Arbutus Biopharma Corporation |
Trialkyl cationic lipids and methods of use thereof
|
|
AU2013240051B2
(en)
|
2012-03-27 |
2017-11-30 |
Sirna Therapeutics, Inc. |
Diether based biodegradable cationic lipids for siRNA delivery
|
|
AU2013299717B2
(en)
|
2012-08-06 |
2018-06-28 |
Alnylam Pharmaceuticals, Inc. |
Carbohydrate conjugated RNA agents and process for their preparation
|
|
WO2015006740A2
(en)
|
2013-07-11 |
2015-01-15 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotide-ligand conjugates and process for their preparation
|
|
JP6620093B2
(ja)
|
2013-07-23 |
2019-12-11 |
アービュートゥス バイオファーマ コーポレイションＡｒｂｕｔｕｓ Ｂｉｏｐｈａｒｍａ Ｃｏｒｐｏｒａｔｉｏｎ |
メッセンジャーｒｎａを送達するための組成物及び方法
|
|
ES3032935T3
(en)
|
2013-10-22 |
2025-07-29 |
Translate Bio Inc |
Lipid formulations for delivery of messenger rna
|
|
AU2014348212C1
(en)
|
2013-11-18 |
2018-11-29 |
Arcturus Therapeutics, Inc. |
Ionizable cationic lipid for RNA delivery
|
|
US9365610B2
(en)
|
2013-11-18 |
2016-06-14 |
Arcturus Therapeutics, Inc. |
Asymmetric ionizable cationic lipid for RNA delivery
|
|
EP3083556B1
(en)
|
2013-12-19 |
2019-12-25 |
Novartis AG |
Lipids and lipid compositions for the delivery of active agents
|
|
US10426737B2
(en)
|
2013-12-19 |
2019-10-01 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
|
HUE060907T2
(hu)
|
2014-06-25 |
2023-04-28 |
Acuitas Therapeutics Inc |
Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
|
|
JP6637988B2
(ja)
|
2014-11-18 |
2020-01-29 |
アークトゥルス セラピューティクス， インコーポレイテッド |
Ｒｎａ送達のためのイオン化可能カチオン性脂質
|
|
US11669953B2
(en)
|
2015-01-30 |
2023-06-06 |
Hitachi High-Tech Corporation |
Pattern matching device and computer program for pattern matching
|
|
PT3313829T
(pt)
|
2015-06-29 |
2024-07-08 |
Acuitas Therapeutics Inc |
Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos
|
|
JP6948313B6
(ja)
|
2015-09-17 |
2022-01-14 |
モデルナティエックス インコーポレイテッド |
治療剤の細胞内送達のための化合物および組成物
|
|
HRP20230209T1
(hr)
|
2015-10-28 |
2023-04-14 |
Acuitas Therapeutics Inc. |
Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
|
|
PL3386484T3
(pl)
|
2015-12-10 |
2022-07-25 |
Modernatx, Inc. |
Kompozycje i sposoby dostarczania środków terapeutycznych
|
|
WO2017117528A1
(en)
|
2015-12-30 |
2017-07-06 |
Acuitas Therapeutics, Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
CA3020585A1
(en)
|
2016-04-11 |
2017-10-19 |
Arbutus Biopharma Corporation |
Targeted nucleic acid conjugate compositions
|
|
US20180020547A1
(en)
|
2016-07-13 |
2018-01-18 |
Alcatel-Lucent Canada Inc. |
Underlying recessed component placement
|
|
CA3075168A1
(en)
*
|
2017-09-08 |
2019-03-14 |
Generation Bio Co. |
Modified closed-ended dna (cedna)
|
|
US12442015B2
(en)
*
|
2018-01-19 |
2025-10-14 |
Generation Bio Co. |
Closed-ended DNA vectors obtainable from cell-free synthesis and process for obtaining ceDNA vectors
|
|
KR20200120649A
(ko)
*
|
2018-02-14 |
2020-10-21 |
제너레이션 바이오 컴퍼니 |
비-바이러스 dna 벡터 및 항체 및 융합 단백질 생산을 위한 이의 용도
|
|
US20230157955A1
(en)
*
|
2020-01-08 |
2023-05-25 |
Puretech Lyt, Inc. |
Vesicle compositions for oral delivery
|